Non-interventional studies in France: a new legal framework in the spotlight
This article was originally published in Scrip
New regulations on non-interventional human studies are close to being adopted in France. They are expected to simplify administrative procedures, and to provide greater legal certainty for pharmaceutical companies conducting such studies, argue Betty Edery and Mikael Salmela of law firm Lovells.
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.